Skip to main content
SpringerLink
Log in

Lichenoide Arzneimittelreaktionen

Lichenoid drug reactions

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Lichenoide Arzneimittelreaktionen sind im Vergleich zu morbilliformen Arzneimittelexanthemen und durch Medikamente ausgelöste Urtikaria selten und mit einzelnen Arzneimitteln bzw. Arzneimittelgruppen wie Goldpräparaten, Antimalariamedikamenten, β‑Blockern und ACE-Hemmern verbunden. Aktuelle Bedeutung hat ihre Verursachung durch Biologika bzw. Medikamente zur „immune checkpoint inhibition“ wie TNF (Tumor-Nekrose-Faktor)-α-Antagonisten und Anti-PD-1(„anti-programme cell death protein 1“)-Antikörper erlangt. Meistens manifestieren sie sich in Form eines Lichen planus mit bevorzugter Lokalisation in UV-Licht-abhängigen Hautatrealen, aber auch Schleimhautbeteiligungen bis hin zu bullösen Formen können auftreten.

Abstract

Lichenoid drug reactions are rare compared to typical morbilliform drug exanthema or urticaria. They are associated with specific drugs or drug families like gold, antimalarial drugs, β‑blockers and angiotensin-converting-enzyme inhibitors. Recent observations included associations with novel drugs such as biologics (e. g. tumour necrosis factor antagonists) and immune checkpoint inhibitors (anti-programme cell death protein 1 antibodies). Lichenoid drug reactions most often resemble lichen planus mainly in areas of ultraviolet-light exposed skin, but also mucosal lichen planus and even bullous lesions may occur.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Ajith C, Dogra S, Handa S (2006) Lichen planus pemphigoides associated with Ramipril. Int J Dermatol 45:1453–1455

    Article  Google Scholar 

  2. An I, Demir V, Akdeniz S (2017) Lichenoid drug eruption induced by colchicine: case report. Cutan Ocul Toxicol 36(2):199–200

    Article  PubMed  Google Scholar 

  3. Asarch A, Gottlieb AB, Lee J, Masterpol KS, Scheinman PL, Stadecker MJ, Massarotti EM, Bush ML (2009) Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-α antagonists. J Am Acad Dermatol 61:104–111

    Article  PubMed  Google Scholar 

  4. Ayers M, Lunceforf J, Nebozhun M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, Piha-Paul SA, Yearly J, Seiwert TY, Ribas A, McClanahan TK (2017) IFN-γ related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 127:2930–2940

    Article  PubMed  PubMed Central  Google Scholar 

  5. Bircher AJ, Scherer K (2010) Delayed cutaneous manifestations of drug hypersensitivity. Med Clin North Am 94(4):711–725

    Article  PubMed  Google Scholar 

  6. Bruynzeel DP, Maibach HI (1998) Patch testing in systemic drug eruptions. In: Kauppinen K, Alanko K, Hannuksela M, Maibach H (Hrsg) Skin reactions to drugs. CRC Press, Boca Raton, S 97–109

    Google Scholar 

  7. Carrozzo M, Uboldi de Capei M, Dametto E, Fasano ME, Arduino P, Broccoletti R, Vezza D, Rendine S, Curtoni ES, Gandolfo S (2004) Tumor necrosis factor-alpha and interferon-gamma polymorphisms contribute to susceptibility to oral lichen planus. J Invest Dermatol 122(1):87–94

    Article  CAS  PubMed  Google Scholar 

  8. Chou S, Hwang SJ, Carlos G, Wakade D, Fernandez-Penas P (2017) Histologic assessment of lichenoid dermatitis observed in patients with advanced malignancies on antiprogramed cell death-1 (anti-PD-1) therapy with or without Ipilimumab. Am J Dermatopathol 39(1):23–27

    Article  PubMed  Google Scholar 

  9. El-Rifaie AA, Rashed LA, Doss RW, Osman ST (2017) MicroRNAs in cutaneous lichen planus. Clin Exp Dermatol 42:896–901

    Article  Google Scholar 

  10. Fessa C, Lim P, Kossard S, Richards S, Peñas PF (2012) Lichen planus-like drug eruptions due to β‑blockers: a case report and literature review. Am J Clin Dermatol 13(6):417–420

    Article  PubMed  Google Scholar 

  11. Fortuna G, Aria M, Schiavo JH (2017) Drug induced oral lichenoid reactions: a real clinical entitiy? A systematic review. Eur J Clin Pharmacol 73:1523–1537

    Article  PubMed  Google Scholar 

  12. Gange RW, Jones EW (1978) Bullous lichen planus caused by labetalol. Br Med J 1(6116):816–817

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Gleichmann E, Kubicka-Muranyi M, Kind P, Goldermann R, Goerz G, Merk H, Rau R (1991) Insights into the mechanism of gold action provided by immunotoxicology: biooxidation of gold(I) to gold(III) detected by sensitized T‑cells. Rheumatol Int 11(4–5):219–220

    Article  CAS  PubMed  Google Scholar 

  14. Goldermann R, Schuppe HC, Gleichmann E, Kind P, Merk H, Rau R, Goerz G (1993) Adverse immune reactions to gold in rheumatoid arthritis: lack of skin reactivity. Acta Derm Venereol 73(3):220–222

    CAS  PubMed  Google Scholar 

  15. Gonzales N, Patel P, Han G (2017) A dissimalar biosimilar?: Lichenoid drug eruption induced by an infliximab biosimilar. Br J Dermatol. https://doi.org/10.1111/bjd.15686

    PubMed  Google Scholar 

  16. Hagen JW, Magro CM, Crowson AN (2012) Emerging adverse cutaneous drug reactions. Dermatol Clin 30:695–730

    Article  CAS  PubMed  Google Scholar 

  17. Halevy S, Sandbank M, Livni E (1993) Macrophage migration inhibition factor release in lichenoid drug reactions. J Am Acad Dermatol 29:263–265

    Article  CAS  PubMed  Google Scholar 

  18. Halevy S (1998) In vitro tests for adverse drug reactions based on cytokine release. In: Kauppinen K, Alanko K, Hannuksela M, Maibach H (Hrsg) Skin reactions to drugs. CRC Press, Boca Raton, S 119–131

    Google Scholar 

  19. Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM (2016) Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 60:190–120

    Article  CAS  PubMed  Google Scholar 

  20. Hussein MRA (2016) Drug-induced skin reactions: a pathologist viewpoint. Cutan Ocul Toxicol 35(1):67–79

    Article  CAS  PubMed  Google Scholar 

  21. Hwang SJ, Carlos G, Wakade D, Byth K, Kong BY, Chou S, Carlino MS, Kefford R, Fernandez-Penas P (2016) Cutaneous adverse events (Aes) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol 74(3):455–461

    Article  PubMed  Google Scholar 

  22. Hwang SJE, Anforth R, Carlos G, Fernandez-Penas P (2017) Cutaneous adverse events of new anti-melanoma therapies: classification and management. Actas Dermosifiliogr 108:6–16

    Article  CAS  PubMed  Google Scholar 

  23. Hwang SJE, Fernández-Peñas P (2018) Adverse reactions to biologics: melanoma (Ipilimumab, Novolumab, Pembrolizumab). In: Puig L, Gulliver W (Hrsg) Adverse reactions to biologics. Curr Probl Dermatol, Bd. 53. Karger, Basel, S 82–92

    Chapter  Google Scholar 

  24. Kauppinen K, Kariniemi AL (1998) Clinical manifestations and histological characteristics. In: Kauppinen K, Alanko K, Hannuksela M, Maibach H (Hrsg) Skin reactions to drugs. CRC Press, Boca Raton, S 25–50

    Google Scholar 

  25. Lehman JS, Tollefson MM, Gibson LE (2009) Lichen planus. Int J Dermatol 48:682–694

    Article  PubMed  Google Scholar 

  26. Lockwood SJ, Prens LM, Kimball AB (2018) Adverse reactions to biologics in psoriasis. In: Puig L, Gulliver W (Hrsg) Adverse reactions to biologics. Curr Probl Dermatol, Bd. 53. Karger, Basel, S 1–14

    Chapter  Google Scholar 

  27. Lorenzo ME, Carter JB, Barnes JA, Nazarian RM (2016) Case 19-2016: a 65-year-old man with end-stage renal disease and a pruritic rash. N Engl J Med 374:2478–2488

    Article  PubMed  Google Scholar 

  28. Payette MJ, Weston G, Humphrey S, Yu J, Holland KE (2015) Lichen planus and other lichenoid dermatoses: kids are not just little people. Clin Dermatol 33(6):631–643

    Article  PubMed  Google Scholar 

  29. Puig L (2018) Paradoxical reactions: anti-tumor necrosis factor α agents, ustekinumab, secukinumab, ixekizumab, and others. In: Puig L, Gulliver W (Hrsg) Adverse reactions to biologics. Curr Probl Dermatol, Bd. 53. Karger, Basel, S 49–63

    Chapter  Google Scholar 

  30. Schaberg KB, Novoa RA, Wakelee HA, Kim J, Cheung C, Srinivas S, Kwong BY (2016) Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J Cutan Pathol 43(4):339–334

    Article  PubMed  Google Scholar 

  31. Skare T, Ribeiro CF, Souza FHM, Haendchen L, Jordão JM (2011) Antimalarial cutaneous side effects: a study in 209 users. Cutan Ocul Toxicol 30(1):45–49

    Article  PubMed  Google Scholar 

  32. Staughton R, Sutton R, Farrell M (1980) beta-Blockers, autoimmunity, and rashes. Lancet 2(8194):581

    Article  CAS  PubMed  Google Scholar 

  33. Turk B, Gunaydin A, Ertam I, Ozturk G (2013) Adverse cutaneous drug reactions among hospitalized patients: five year surveillance. Cutan Ocul Toxicol 32(1):41–45

    Article  CAS  PubMed  Google Scholar 

  34. Zheng Y, Zhang J, Chen H, Lai W, Maibach HI (2017) Terbinafine-induced lichenoid drug eruption. Cutan Ocul Toxicol 36(1):101–103

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Dermatologie & Allergologie, RWTH Aachen University, Aachen, Deutschland

    H. F. Merk, L. Vanstreels & M. Megahed

Authors
  1. H. F. Merk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Vanstreels
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Megahed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. F. Merk.

Ethics declarations

Interessenkonflikt

H.F. Merk, L. Vanstreels und M. Megahed geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren. Alle Patienten, die über Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts zu identifizieren sind, haben hierzu ihre schriftliche Einwilligung gegeben. Im Falle von nicht mündigen Patienten liegt die Einwilligung eines Erziehungsberechtigten oder des gesetzlich bestellten Betreuers vor.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Merk, H.F., Vanstreels, L. & Megahed, M. Lichenoide Arzneimittelreaktionen. Hautarzt 69, 116–120 (2018). https://doi.org/10.1007/s00105-017-4117-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-017-4117-y

Schlüsselwörter

Keywords

Search

Navigation